The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Inhibition of WNT5A Signaling and Function in Malignant Melanoma


  • Rickard Linnskog

Summary, in English

The life-threatening disease of malignant melanoma is one of the fastest growing forms of cancer, affecting an estimated number of 200,000 patients worldwide every year. Although highly curable if detected early, once the melanoma has metastasized there are few treatment options and a median survival rate of only 6-9 months. Consequently, there is an imperative need to identify the factors that drive melanoma metastasis and to develop means of interfering with their actions.

Elevated WNT5A expression has been significantly correlated with increased metastatic potential of melanoma cells as well as reduced patient survival. In this thesis we investigate the possibility of impairing melanoma cell motility by targeting WNT5A signaling. Our results demonstrate that TGFβ is an unsuitable target for blocking WNT5A signaling since it mediates unpredictable effects on melanoma cell invasion. Instead, we show that the t-butyloxycarbonyl-modified WNT5A-derived hexapeptide Box5 functions a potent antagonist of WNT5A-induced signaling, migration and invasion in melanoma cells. Moreover, we demonstrate that IL-6 can drive melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression and that targeting IL-6, in contrast to TGFβ, reduces melanoma cell invasion. We furthermore reveal the existence of a WNT5A-IL-6 positive feedback loop in melanoma cells that augments their invasive capacity. Concomitantly, we show that combined targeting of IL-6 and WNT5A within this loop more effectively impairs melanoma cell invasion.

Taken together, our results demonstrate the possibilities of antagonizing WNT5A signaling directly (Box5) or indirectly (targeting of IL-6), which if combined can provide the basis for future therapeutic intervention of melanoma metastasis.


Publishing year





Lund University Faculty of Medicine Doctoral Dissertation Series



Document type



Department of Laboratory Medicine, Lund University


  • Clinical Medicine


  • WNT5A
  • Malignant Melanoma
  • Migration
  • Invasion
  • TGFβ
  • IL-6
  • p38-MAPK



Research group

  • Experimental Pathology, Malmö
  • Experimental Cancer Research, Malmö



  • ISSN: 1652-8220
  • ISBN: 978-91-7619-043-2

Defence date

10 October 2014

Defence time


Defence place

Main lecture hall. Pathology building, Skåne University Hospital, Malmö


  • Ashani Weeraratna